Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Dysmenorrhea is associated with a higher incidence of pain after diagnostic hysteroscopy or treatment
1Department of Anesthesia, The First Affiliated Hospital of Wenzhou Medical University, 325000 Wenzhou, P. R. China
2Department of Anesthesia , Wenzhou People's Hospital ,325000 Wenzhou, P. R. China
*Corresponding Author(s): Yuan-Yuan Pan E-mail: panyuanyuan0102@163.com
† These authors contributed equally.
Purpose: The purpose of this study was to evaluate whether dysmenorrhea could predict the occurrence of pain perceived after diagnostic hysteroscopy or treatment.
Methods: 58 women undergoing diagnostic hysteroscopy or treatment were divided into two groups: patients with dysmenorrhea (Group A) and patients without dysmenorrhea (Group B). Patients underwent routine monitoring after the administration of 7.5 µg of sufentanil by intravenous injection. Propofol infusion was initiated by using a target-controlled infusion pump with concentration initially set at 2 µg/mL in order to maintain a bispectral index monitor (BIS) of 60 to 80. Remifentanil was administered as continuous infusion at 0.05 µg/kg per minute. The total dose of propofol and remifentanil utilized during the procedure was calculated.
Results: There were no differences in the characteristics of patients in either group. Multivariate analysis revealed that the presence of dysmenorrhea was significantly correlated with pain (P < 0.05) following the procedure.
Conclusion: Dysmenorrhea is associated with a higher incidence of pain after diagnostic hysteroscopy.
Dysmenorrhea; Diagnostic hysteroscopy; Pain
Yuan-Yuan Pan,Shen-Hui Jin,Shan Luo,Ru-Ru Li,Ying-Ying Tu,Dan Jin,Wen-Jun Jin,Xiu-Xiu Zhuang,Jun-Lu Wang. Dysmenorrhea is associated with a higher incidence of pain after diagnostic hysteroscopy or treatment. Signa Vitae. 2021. 17(2);63-66.
[1] Sutton C. Hysteroscopic surgery. Best Practice & Research: Clinical Obstetrics & Gynaecology. 2006; 20: 105-137.
[2] Giannella L, Mfuta K, Cerami LB, Boselli F. Does uterine position affect pain intensity during outpatient diagnostic hysteroscopy? Clinical and Experimental Obstetrics & Gynecology. 2019; 46: 787-791.
[3] Pellicano M, Guida M, Zullo F, Lavitola G, Cirillo D, Nappi C. Carbon dioxide versus normal saline as a uterine distension medium for diagnostic vaginoscopic hysteroscopy in infertile patients: a prospective, randomized, multicenter study. Fertility and Sterility. 2003; 79: 418-421.
[4] Rullo S, Sorrenti G, Marziali M, Ermini B, Sesti F, Piccione E. Office hysteroscopy: comparison of 2.7- and 4-mm hysteroscopes for acceptability, feasibility and diagnostic accuracy. The Journal of Reproductive Medicine. 2005; 50: 45-48.
[5] Floris S, Piras B, Orrù M, Silvetti E, Tusconi A, Melis F, et al. Efficacy of intravenous tramadol treatment for reducing pain during office diagnostic hysteroscopy. Fertility and Sterility. 2007; 87: 147-151.
[6] Unfried G, Wieser F, Albrecht A, Kaider A, Nagele F. Flexible versus rigid endoscopes for outpatient hysteroscopy: a prospective randomized clinical trial. Human Reproduction. 2001; 16: 168-171.
[7] Garbin O, Kutnahorsky R, Göllner JL, Vayssiere C. Vaginoscopic versus conventional approaches to outpatient diagnostic hysteroscopy: a two-centre randomized prospective study. Human Reproduction (Oxford, England). 2007; 21: 2996-3000.
[8] El-Mazny A, Abou-Salem N. A double-blind randomized controlled trial of vaginal misoprostol for cervical priming before outpatient hysteroscopy. Fertility and Sterility. 2011; 96: 962-965.
[9] de Carvalho Schettini JA, Ramos de Amorim MM, Ribeiro Costa AA, Albuquerque Neto LC. Pain evaluation in outpatients undergoing diagnostic anesthesia-free hysteroscopy in a teaching hospital: a cohort study. Journal of Minimally Invasive Gynecology. 2007; 14: 729-735.
[10] de Carvalho Schettini JA, Ramos de Amorim MM, Ribeiro Costa AA, Albuquerque Neto LC. Pain evaluation in outpatients undergoing diagnostic anesthesia-free hysteroscopy in a teaching hospital: a cohort study. Journal of Minimally Invasive Gynecology. 2007; 14: 729-735.
[11] de Freitas Fonseca M, Sessa FV, Resende JAD, Guerra CGS, Andrade CM, Crispi CP. Identifying predictors of unacceptable pain at office hysteroscopy. Journal of Minimally Invasive Gynecology. 2014; 21: 586-591.
[12] Chudnoff S, Einstein M, Levie M. Paracervical block efficacy in office hysteroscopic sterilization: a randomized controlled trial. Obstetrics and Gynecology. 2010; 115: 26-34.
[13] Hassan L, Gannon MJ. Anaesthesia and analgesia for ambulatory hysteroscopic surgery. Best Practice & Research: Clinical Obstetrics & Gynaecology. 2006; 19: 681-691.
[14] Kapila A, Glass PS, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995; 83: 968-975.
[15] Dilger JA, Sprung J, Maurer W, Tetzlaff J. Remifentanil provides better analgesia than alfentanil during breast biopsy surgery under monitored anesthesia care. Canadian Journal of Anesthesia. 2004; 51: 20-24.
[16] de Carvalho Schettini JA, Ramos de Amorim MM, Ribeiro Costa AA, Albuquerque Neto LC. Pain evaluation in outpatients undergoing diagnostic anesthesia-free hysteroscopy in a teaching hospital: a cohort study. Journal of Minimally Invasive Gynecology. 2007; 14: 729-735.
[17] Rosow CE. An overview of remifentanil. Anesthesia & Analgesia. 1999; 89: 1.
[18] Servin F, Desmonts JM, Watkins WD. Remifentanil as an analgesic adjunct in local/regional anesthesia and in monitored anesthesia care. Anesthesia & Analgesia. 1999; 89: 28.
[19] Gold M, Watkins W Sung Y, Yarmush J, Chung F, Uy N, et al. Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. Anesthesiology. 1997; 87: 51-57.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 1.3 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.
Top